Company research
Evommune, Inc.
CIK 2044725Updated Sep 24, 2026
SecurityEVMN · NYSE · equity
EVMN price & chart
Loading TradingView…
NYSE:EVMN on TradingView ↗About the company
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.
In the news
NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading USA - English APAC - English News provided by New York Stock Exchange Nov 06, 2025, 08:55 ET Share this article Share to X Share this article Share to X NEW YORK , Nov. 6, 2025 /PRNewswire/ -- The New York Stock Exchange ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
424B3 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
SCHEDULE 13G/A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 224,946,000Source | 76,055,000Source |
| Property, Plant and Equipment, NetUSD | 994,000Source | 1,326,000Source |
| Current assets: | ||
| Cash and Cash Equivalents, at Carrying ValueUSD | 44,063,000Source | 16,255,000Source |
| Assets, CurrentUSD | 153,478,000Source | 73,988,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,278,000Source | 1,948,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,469,000Source | 472,000Source |
| Other Assets, NoncurrentUSD | 101,000Source | 61,000Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 19,380,000Source | 28,516,000Source |
| Stockholders’ equity: | ||
| Common Stock, Value, IssuedUSD | 3,000Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -221,089,000Source | -152,219,000Source |
| Stockholders' Equity Attributable to ParentUSD | 205,566,000Source | -144,237,000Source |
| Additional Paid in Capital, Common StockUSD | 426,652,000Source | 7,982,000Source |
| Liabilities and EquityUSD | 224,946,000Source | 76,055,000Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 17,909,000Source | 27,981,000Source |
| Operating Lease, Liability, CurrentUSD | 242,000Source | 487,000Source |
| Accounts Payable, CurrentUSD | 7,756,000Source | 8,264,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,290,000Source | — |
| Additional Financial Items | ||
| Accrued Liabilities, CurrentUSD | 9,547,000Source | 6,729,000Source |
| Short-term InvestmentsUSD | 105,137,000Source | 55,785,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -68,870,000Source | -66,808,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation, Depletion and AmortizationUSD | 600,000Source | 500,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,856,000Source | 1,722,000Source |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts PayableUSD | -837,000Source | 6,506,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -76,441,000Source | -58,195,000Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -115,307,000Source | -3,993,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 235,000Source | 88,000Source |
| Cash flows from financing activities: | ||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 1,224,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 220,763,000Source | 49,419,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 29,015,000Source | -12,769,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 45,478,000Source | 16,463,000Source |
| Supplemental disclosure of cash flow information: | ||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 7,000Source | 34,000Source |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 5,856,000Source | 1,722,000Source |
| General and Administrative ExpenseUSD | 20,029,000Source | 12,769,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Investment Income, InterestUSD | 3,323,000Source | 3,242,000Source |
| Net Income (Loss) Attributable to ParentUSD | -68,870,000Source | -66,808,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -68,870,000Source | -68,308,000Source |
| Operating ExpensesUSD | 94,071,000Source | 77,013,000Source |
| Other Nonoperating Income (Expense)USD | 12,201,000Source | 3,205,000Source |
| Payments to Acquire InvestmentsUSD | 199,172,000Source | 90,255,000Source |
| Proceeds from Stock Options ExercisedUSD | 6,000Source | 13,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 13,000,000Source | 7,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Total RevenueUSD | 13,000,000Source | 7,000,000Source |
| Operating Income (Loss)USD | -81,071,000Source | -70,013,000Source |
| Other Nonoperating Income (Expense)USD | 12,201,000Source | 3,205,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -68,870,000Source | -68,308,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -68,870,000Source | -66,808,000Source |
| Earnings Per Share, BasicUSD per share | -11.22Source | -45.29Source |
| Earnings Per Share, DilutedUSD per share | -11.22Source | -45.29Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 6,136,636Source | 1,508,284Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 6,136,636Source | 1,508,284Source |
| Additional Financial Items | ||
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,389,000Source | 1,287,000Source |
| General and Administrative ExpenseUSD | 20,029,000Source | 12,769,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -68,870,000Source | -68,308,000Source |
| Investment Income, InterestUSD | 3,323,000Source | 3,242,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -68,870,000Source | -68,308,000Source |
| Operating ExpensesUSD | 94,071,000Source | 77,013,000Source |
| Research and Development ExpenseUSD | 74,042,000Source | 64,244,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 13,000,000Source | 7,000,000Source |
Offerings
Registration 333-295140
Registration 333-290793
- Gross proceeds
- 150000000.0
- Net proceeds
- 139500000.0
- Deal price
- 16.0
- Shares
- 9375000
- Offering price
- $16.00
- Ticker
- EVMN
Filing attachments
evmn-ex99_1.htm · 8-K · 2026-09-23
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress Palo Alto, Calif., and New York, September 23, 2026 - Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis …
Read attachment ↗evmn-ex99_1.htm · 8-K · 2026-09-15
EX-99.1 2 evmn-ex99_1.htm EX-99.1 Evommune Corporate Presentation September 2026 © Evommune, Inc. Disclaimers This presentation has been prepared by Evommune, Inc. (“we”, “us” or “our”) and contains forward-looking statements, including: statements about our expectations regarding the potential benefits, clinical activity and tolerability of our product candidates; our expectations with regard to the results of our clinical trials, preclinical studies and research and development programs, …
Read attachment ↗evmn-ex99_1.htm · 8-K · 2026-09-09
EX-99.1 2 evmn-ex99_1.htm EX-99.1 EX-99.1 Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis ‑ Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated ‑ EVO301, the Company’s IL-18BP fusion protein, advances as lead atopic dermatitis program following positive Phase 2a proof-of-concept data ‑ Evommune to continue Phase 2b devel…
Read attachment ↗evmn-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 evmn-ex99_1.htm EX-99.1 EX-99.1 Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027 ‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference ‑ Strong balance sheet, with cash th…
Read attachment ↗evmn-ex99_1.htm · 8-K · 2026-07-30
EX-99.1 2 evmn-ex99_1.htm EX-99.1 EX-99.1 Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis ‑ MRGPRX2 receptor expressed in human trigeminal neurons and meningeal mast cells, the two key disease-relevant tissues in migraine biology ‑ EVO756 designed to inhibit three key neuropeptides (PACAP, VIP, Substance P) that trigger migraine signal through MRGPRX2 ‑ Top-line data expected in 2027 Palo Alto, Calif., and New York, July 30, 2026 - Evommune…
Read attachment ↗evmn-ex99_1.htm · 8-K · 2026-06-29
EX-99.1 2 evmn-ex99_1.htm EX-99.1 EX-99.1 Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria ‑ Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks ‑ Evommune to continue development of EVO756 in Atopic Dermatitis and Migraine Palo Alto, Calif., and New York, June 29, 2026 - Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnolo…
Read attachment ↗